Pharma trends in emerging markets
Slow growth in pharmaceutical sales over recent years has spurred considerable interest and investment into emerging global markets: Brazil, Russia, India, China and South Korea (BRICS).
The main reason behind this trend is cost efficiency of establishing off-shore manufacturing sites in those countries; and also setting them as new target markets, given their ever evolving demographics, healthcare affordability and accessibility, says research and consulting firm GlobalData. Over the past six years, company revenue compound average growth rates (CAGR) in Russia, India, China and South Korea averaged at 7.2%, exceeding that of USA where a CAGR of 6% was observed.
The research was conducted so as to assess the potential and examine current trends in the pharmaceutical industry in Brazil, Russia, India, China and South Korea.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze